This was a global, open-label, randomized phase III trial evaluating the efficacy of sotorasib versus docetaxel in KRAS mutant NSCLC patients who progressed after prior platinum-based chemotherapy and a checkpoint inhibitor. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.